Investigation Report on China Celecoxib Market, 2010-2019
Description
Currently, there are over 30 million people around the world using non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory pain-relief drugs. However, many drugs under the category of NSAIDs cause gastrointestinal adverse reactions such as ulcer, perforation and bleeding. The latest research has shown that among all the NSAIDs, celecoxib reports the lowest number of cases of gastrointestinal side effects. As a kind of NASIDs, celecoxib is mainly used for osteoarthritis, rheumatoid arthritis and the adjuvant treatment of familial adenomatous polyposis. It is reported that over 100 million people in China suffer from arthritis, among which about 10% use celecoxib.
Developed by GD Searle & Pfizer, celecoxib came into the market in 1999 under the trade name of Celebrex. Ever since its debut in the US in Feb. 1999, celecoxib has been widely used and set a record for the largest amount of prescriptions among all the new drugs in that year. Celecoxib has become the No. 1 brand of anti-rheumatic drug with a reputation as the most successful branded drug in the market.
In Sep. 2000, celebrex (celecoxib capsule) made by Pfizer Inc was approved by CFDA to enter China. Celecoxib develops fast then, annual sales rising from CNY 20 million in 2005 to CNY 164 million in 2014 and CAGR reaching up to 24.59% during the period of 2005-2014. Celecoxib enjoys a vast demand in China. Currently, celecoxib in the Chinese market mainly come from two companies: Pfizer Inc and Shire Plc. They monopolize the Chinese market and Pfizer has a larger market share of over 98%, sales value reaching up to CNY 162 million in 2014.
The market size of celecoxib is expected to keep expanding in China in the next few years.
Readers can get at least the following information from this report:
Currently, there are over 30 million people around the world using non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory pain-relief drugs. However, many drugs under the category of NSAIDs cause gastrointestinal adverse reactions such as ulcer, perforation and bleeding. The latest research has shown that among all the NSAIDs, celecoxib reports the lowest number of cases of gastrointestinal side effects. As a kind of NASIDs, celecoxib is mainly used for osteoarthritis, rheumatoid arthritis and the adjuvant treatment of familial adenomatous polyposis. It is reported that over 100 million people in China suffer from arthritis, among which about 10% use celecoxib.
Developed by GD Searle & Pfizer, celecoxib came into the market in 1999 under the trade name of Celebrex. Ever since its debut in the US in Feb. 1999, celecoxib has been widely used and set a record for the largest amount of prescriptions among all the new drugs in that year. Celecoxib has become the No. 1 brand of anti-rheumatic drug with a reputation as the most successful branded drug in the market.
In Sep. 2000, celebrex (celecoxib capsule) made by Pfizer Inc was approved by CFDA to enter China. Celecoxib develops fast then, annual sales rising from CNY 20 million in 2005 to CNY 164 million in 2014 and CAGR reaching up to 24.59% during the period of 2005-2014. Celecoxib enjoys a vast demand in China. Currently, celecoxib in the Chinese market mainly come from two companies: Pfizer Inc and Shire Plc. They monopolize the Chinese market and Pfizer has a larger market share of over 98%, sales value reaching up to CNY 162 million in 2014.
The market size of celecoxib is expected to keep expanding in China in the next few years.
Readers can get at least the following information from this report:
- market size of celecoxib in China
- market share of manufacturers of celecoxib in China
- price of celecoxib in Chinese market
- major manufacturers of celecoxib in Chinese market
- market outlook of celecoxib in China The author suggests the following groups of people purchase this report:
- manufacturers of NSAIDs
- investors/ research institutions interested in Chinese medicine market
- any interest in the Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF CELECOXIB
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF CELECOXIB IN CHINA
2.1 Patent and Approval Status of Celecoxib in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF CELECOXIB IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.1 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF CELECOXIB IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF CELECOXIB IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF CELECOXIB IN CHINESE HOSPITALS IN 2014
6.1 Shire Plc (Trade Name: Celebrex)
6.2 Pfizer Inc (Trade Name: Celebrex)
7 MAJOR MANUFACTURERS OF CELECOXIB IN CHINESE MARKET, 2010-2014
7.1 Pfizer Inc
7.2 Shire Plc
8 MARKET OUTLOOK OF CELECOXIB IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF CELECOXIB IN CHINA
2.1 Patent and Approval Status of Celecoxib in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF CELECOXIB IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.1 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF CELECOXIB IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF CELECOXIB IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF CELECOXIB IN CHINESE HOSPITALS IN 2014
6.1 Shire Plc (Trade Name: Celebrex)
6.2 Pfizer Inc (Trade Name: Celebrex)
7 MAJOR MANUFACTURERS OF CELECOXIB IN CHINESE MARKET, 2010-2014
7.1 Pfizer Inc
7.2 Shire Plc
8 MARKET OUTLOOK OF CELECOXIB IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
SELECTED CHARTS
Chart Approval Information of Celecoxib in China
Chart Sales Status of Celecoxib in China
Chart Sales Value of Celecoxib in China, 2010-2014
Chart Sales Value of Celecoxib in Some Regions in China, 2010-2014
Chart Sales Volume of Celecoxib in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Celecoxib for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Celecoxib Made by Pfizer (the US) in China, 2010-2014
Chart Sales Value and Market Share of Celecoxib Made by Shire (the US) in China, 2010-2014
Chart Sales Value and Market Share of Celecoxib Capsules in China, 2010-2014
Chart Price of Celecoxib Made by Shire Plc (the US) in Some Chinese Cities in 2014
Chart Price of Celecoxib Made by Pfizer Inc (the US) in Some Chinese Cities in 2014
Chart Approval Information of Celecoxib in China
Chart Sales Status of Celecoxib in China
Chart Sales Value of Celecoxib in China, 2010-2014
Chart Sales Value of Celecoxib in Some Regions in China, 2010-2014
Chart Sales Volume of Celecoxib in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Celecoxib for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Celecoxib Made by Pfizer (the US) in China, 2010-2014
Chart Sales Value and Market Share of Celecoxib Made by Shire (the US) in China, 2010-2014
Chart Sales Value and Market Share of Celecoxib Capsules in China, 2010-2014
Chart Price of Celecoxib Made by Shire Plc (the US) in Some Chinese Cities in 2014
Chart Price of Celecoxib Made by Pfizer Inc (the US) in Some Chinese Cities in 2014
